Format

Send to

Choose Destination
Endocrinol Diabetes Nutr. 2017 Aug - Sep;64(7):377-383. doi: 10.1016/j.endinu.2017.04.006. Epub 2017 Jun 7.

Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain.

[Article in English, Spanish]

Author information

1
Unidad de Diabetes, Servicio de Endocrinología y Nutrición, ICMDiM, Hospital Clínic i Universitari de Barcelona, IDIBAPS, Barcelona, España. Electronic address: gimenez@clinic.ub.es.
2
Health Economics & Outcomes Research, Medtronic Ibérica, S.A., Madrid, España.
3
Unidad de Diabetes, Servicio de Endocrinología y Nutrición, ICMDiM, Hospital Clínic i Universitari de Barcelona, IDIBAPS, Barcelona, España.

Abstract

OBJECTIVE:

Hypoglycemia is one of the most common complications to achieve a good metabolic control, and has been listed by several scientific associations as a common indication to start treatment with continuous subcutaneous insulin infusion (CSII). Use of CSII is still residual in Spain as compared to neighbouring countries, and cost of acquisition cost is one of the main reasons. This study estimates the budget impact of treatment with CSII, as compared to multiple daily insulin injections, of patients with type 1 diabetes mellitus who experience recurrent severe hypoglycemia episodes from the National Healthcare System perspective.

METHODS:

Budget impact was based on a retrospective, observational study evaluating the efficacy of CSII in patients with type 1 diabetes mellitus conducted at Hospital Clínic i Universitari in Barcelona, where one of the main indications for switching to CSII were recurrent severe hypoglycemia episodes. The mean number of annual episodes was 1.33 in the two years prior to CSII start and 0.08 in the last two years of follow up (p=0.003). Costs of treatment and major hypoglycemic events over a four-year period were considered. Costs were taken from different Spanish data sources and expressed in € of 2016.

RESULTS:

Treatment with CSII increased costs by €9,509 per patient as compared to multiple daily insulin injections (€11,902-€2,393). Cost associated to severe hypoglycemic events decreased by €19,330 per patient treated with CSIII (€1,371-€20,701). Results suggest mean total savings of €9,821 per patient during the four-year study period.

CONCLUSION:

The higher costs associated to CSII therapy may be totally offset by the severe hypoglycemic events prevented.

KEYWORDS:

Continuous subcutaneous insulin infusion; Costes directos sanitarios; Diabetes mellitus tipo 1; Direct healthcare costs; España; Hipoglucemia grave; Infusión subcutánea continua de insulina; Multiple daily insulin injections; Múltiples dosis de insulina; Severe hypoglycemia; Spain; Type 1 diabetes mellitus

PMID:
28745609
DOI:
10.1016/j.endinu.2017.04.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center